T

TriSalus Life Sciences, Inc. (TLSI)

NGM – Real vaqt narxi. Valyuta: USD

4.56

+0.02 (0.44%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

T

TriSalus Life Sciences, Inc. (TLSI)

NGM – Real vaqt narxi. Valyuta: USD

4.56

+0.02 (0.44%)

Yopilishda: May 12, 2026, 4:00 PM EDT

13.05.2026

TriSalus Life Sciences Q1 Earnings Call Highlights

TriSalus Life Sciences NASDAQ: TLSI reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.

12.05.2026

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.33 per share a year ago.

12.05.2026

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended March 31, 2026, and provided an operational update. “The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our c.

12.05.2026

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in trans-arterial chemoemboliz.

04.05.2026

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients w.

28.04.2026

TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. A press release detailing the.

09.04.2026

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical a.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended March 31, 2026, and provided an operational update. “The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our c.

12.05.2026

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in trans-arterial chemoemboliz.

04.05.2026

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients w.

07.04.2026

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Di.

Search stocks

TriSalus Life Sciences, Inc. (TLSI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TriSalus Life Sciences, Inc. (TLSI)

TriSalus Life Sciences Q1 Earnings Call Highlights

TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call

TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting

Videolar

No Data

Press-relizlar

TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth

Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance

TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors

TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer